Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21ClN5O5P |
| Molecular Weight | 465.827 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C)C=NC(CN2C=C(C#CCCOP(O)(O)=O)C3=C(Cl)N=C(N)N=C23)=C1C
InChI
InChIKey=BMZGPNGECPQAGB-UHFFFAOYSA-N
InChI=1S/C19H21ClN5O5P/c1-11-8-22-14(12(2)16(11)29-3)10-25-9-13(6-4-5-7-30-31(26,27)28)15-17(20)23-19(21)24-18(15)25/h8-9H,5,7,10H2,1-3H3,(H2,21,23,24)(H2,26,27,28)
| Molecular Formula | C19H21ClN5O5P |
| Molecular Weight | 465.827 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:37:18 UTC 2023
by
admin
on
Sat Dec 16 11:37:18 UTC 2023
|
| Record UNII |
KD4GWWK597
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C78846
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
PRIMARY | |||
|
BIIB-028
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
PRIMARY | Description: BIIB028 is a small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2/Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses. | ||
|
KD4GWWK597
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
PRIMARY | |||
|
1315607-68-1
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
NO STRUCTURE GIVEN | |||
|
911398-13-5
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
PRIMARY | |||
|
57713852
Created by
admin on Sat Dec 16 11:37:18 UTC 2023 , Edited by admin on Sat Dec 16 11:37:18 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Memorial Sloan-Kettering Cancer Center; Developer: Biogen; Class: Antineoplastic, Small molecule; Mechanism of Action: HSP90 heat-shock protein inhibitor; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 17 Mar 2011 Biogen Idec completes enrolment in its phase I trial for Solid tumours in USA (NCT00725933), 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec, 29 Oct 2001 Preclinical trials in Solid tumours (IV)
|
